Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update Aug 4, 2022
Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America Aug 2, 2022
Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update May 11, 2022
Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update Apr 29, 2022
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update Mar 17, 2022
Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT Mar 16, 2022
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update Mar 7, 2022
Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases Feb 7, 2022
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) Dec 6, 2021